Pall T. Onundarson: Fiix-Monitored Warfarin is Actually More Effective than Unmonitored DOACs!
Pall T. Onundarson, Professor Emeritus at Landspitali University Hospital, recently shared an insightful post on LinkedIn:
”Convenient DOAC drugs have been forced to replace conventional PT-INR monitored VKAs to a large degree in patients with AF and VTE while conventional PT-INR monitored VKAs remains used for other conditions where VKAs have been shown to be more effective or safer. Observational data from Germany and the UK suggest lower mortality in VKA treated AF patients.
Would it change the scenario if the effectiveness of VKAs could be enhanced by using a more modern monitoring method than the PT-INR? How would that influence prescriptions?
For patients needing VKAs such as warfarin, isn´t it amazing that most of the world continues to use an old suboptimal test (PT-INR) to monitor and dose them when a better method exists?
There are only historical reasons for using the old Quick-PT or the Owren´s PT to calculate a normalized ratio; these tests were developed prior to full understanding of coagulation and the antithrombotic effect of VKAs.
Do suboptimal tests cause erroneous tailoring of the dose and consequent suboptimal outcomes? Our 3 clinical studies have found better patient outcomes with Fiix (factor II and X only) monitored warfarin than with conventional PT-monitored warfarin – and suggestive evidence that Fiix-monitored warfarin is actually more effective than unmonitored DOAC drugs in non-valvular atrial fibrillation patients.
These data showing more effective and more convenient warfarin management using Fiix monitoring appears not to interest many. In particular not cardiologists and clinical scientists that have been supported by drug companies. Still the data supporting that factor VII should be ignored during VKA monitoring are there in peer reviewed journals, including in The Lancet Haematology 2015, Blood 2021 and Blood VTH 2025. These results have not been contested but remain ignored.
Is it possible that medical doctors prioritize convenience of prescription over effectiveness? Convenience for patients over less disability and death? How do patients and health authorities feel about that if true?”
Stay informed on the latest scientific developments in coagulation with Hemostasis Today.
-
Nov 4, 2025, 09:26Courtney Lawrence: One of Our Most Popular American Red Cross SUCCESS Talks is Just Around the Corner!
-
Nov 4, 2025, 09:21New Study by Emmanuel J Favaloro and Team Questions Consistency in APS Classification and Diagnosis
-
Nov 4, 2025, 09:20Yazan Abou Ismail to Present Insights on AI Models in TTP at 67th ASH Annual Meeting
-
Nov 4, 2025, 09:17David Calvet Canut on Takeda's HyHub: A Shift Toward Patient-Centered Biologics
-
Nov 4, 2025, 09:16Samantha Nelson Encourages You to Share Your Experience on World Thrombosis Day
-
Nov 4, 2025, 08:57Toluwalase Awoyemi: Digital Health Meets Maternal Heart Care
-
Nov 4, 2025, 08:53Rebecca Ahrens Nicklas Shares FDA Interactions on Interventional Genetics with The Rare Disease Community
-
Nov 3, 2025, 09:13Claudio Carrubba on How Timing Truly Matters in Trauma Embolization
-
Nov 3, 2025, 08:57Multiplex Apolipoprotein Panel Boosts Cardiovascular Risk Prediction and Precision Therapy
-
Nov 3, 2025, 08:46Rachel Lamerton and Colleagues on Activation of Platelets in Flow Cytometry
-
Nov 4, 2025, 09:10OCCUPI Trial Analysis Highlights Benefits of OCT Guidance in ACS Patients
-
Oct 29, 2025, 07:31The Use of Artificial Intelligence to Improve Detection of Acute Incidental Pulmonary Emboli - JTH
-
Oct 29, 2025, 07:05Shrinidhi Nathany: AI in Diagnostic Medicine
-
Oct 28, 2025, 07:02Aya Berman: AI Model for Predicting Bacteremia
-
Oct 28, 2025, 06:55The New Era of Genomics, AI and Cell Therapy in Hematology and Infectious Diseases
-
Nov 4, 2025, 09:17HaemophiliaIRL Series Begins․ Advances in von Willebrand Disease Treatment
-
Nov 4, 2025, 09:14Exploring Molecular Pathways of Aging in Hematopoiesis․ FEBS Workshop 2025
-
Nov 4, 2025, 08:28Fritz Roth Thanks Supporters of Science Magazine Study Linking Genes to High Cholesterol and Heart Attack Risk
-
Nov 4, 2025, 08:22Colleen Silk on Novo Nordisk Taking the 2025 Prix Galien US Award
-
Nov 4, 2025, 08:14Cristina Anton: Excited to Be Part of Women in Hematology!